stars 1 stars 2 stars 3

A-Alpha Bio is a biotechnology platform company building the foundational data layer for AI-driven protein engineering. Through Atlas, its data platform, A-Alpha Bio provides biopharma companies and model builders with access to ground truth datasets, including affinity and structure, for training, benchmarking and validating AI protein models. Its experimental platform, AlphaSeq, enables the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously—a scale at least four orders of magnitude beyond that of existing biophysical methods. A-Alpha Bio also applies its data and models directly with select partners to engineer next-generation dual-specific and molecular glue therapeutics, and to discover and optimize differentiated biologics. A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington's Institute for Protein Design.

A-Alpha Bio Questions

The A-Alpha Bio annual revenue was $9.5 million in 2026.

David Younger is the Co-Founder and CEO of A-Alpha Bio.

36 people are employed at A-Alpha Bio.

Top A-Alpha Bio Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users